Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9,810 JPY | 0.00% | +6.17% | +37.59% |
03-25 | Towa Pharmaceutical Completes Payment for Director Stock Compensation | MT |
02-07 | Towa Corporation Provides Dividend Guidance for the Year Ending March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 41.69 and 27.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.91 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Semiconductor Equipment & Testing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+37.59% | 1.6B | - | ||
+25.93% | 170B | A- | ||
+32.90% | 32.94B | C- | ||
+27.42% | 31.75B | B+ | ||
-18.70% | 27.27B | - | ||
+29.83% | 23.4B | C | ||
-7.77% | 12.14B | C- | ||
-8.13% | 10.4B | B+ | ||
+110.70% | 9.26B | - | ||
+33.93% | 6.25B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6315 Stock
- Ratings TOWA Corporation